Provided by Tiger Trade Technology Pte. Ltd.

Sarepta Therapeutics

18.79
-0.4300-2.24%
Pre-market: 18.75-0.0400-0.21%05:48 EDT
Volume:1.67M
Turnover:31.88M
Market Cap:1.98B
PE:-14.28
High:19.73
Open:19.39
Low:18.66
Close:19.22
52wk High:25.32
52wk Low:14.68
Shares:105.57M
Float Shares:99.05M
Volume Ratio:0.66
T/O Rate:1.69%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.3161
EPS(LYR):-7.1300
ROE:-9.48%
ROA:-1.13%
PB:1.30
PE(LYR):-2.64

Loading ...

Sarepta Therapeutics Eyes 2026 Reset After Rocky Year

TIPRANKS
·
Mar 03

Stock Track | Sarepta Therapeutics Plummets 5.01% Intraday on Analyst Price Target Cuts

Stock Track
·
Mar 02

Sarepta price target lowered to $29 from $34 at Wedbush

TIPRANKS
·
Mar 02

Wedbush Adjusts Sarepta Therapeutics PT to $29 From $34, Maintains Outperform Rating

MT Newswires Live
·
Mar 02

Sarepta Therapeutics Price Target Maintained With a $5.00/Share by HC Wainwright & Co.

Dow Jones
·
Mar 02

Stock Track | Sarepta Therapeutics Plummets 5.16% Intraday Following Wells Fargo Price Target Cut

Stock Track
·
Feb 28

Sarepta Therapeutics Is Maintained at Overweight by Wells Fargo

Dow Jones
·
Feb 28

Sarepta Therapeutics Announces Call for Applications for the 9TH Annual Route 79, the Duchenne Scholarship Program

THOMSON REUTERS
·
Feb 27

Sarepta price target lowered to $38 from $45 at Wells Fargo

TIPRANKS
·
Feb 27

ETF Daily | IONX Soars 42%; NUGT Gains 5%; SQQQ Rises 4%; Tech Soft, Gold Miners Lead

Tiger Newspress
·
Feb 27

Sarepta Therapeutics Shares Down 9% After Bigger-Than-Expected Q4 Loss

THOMSON REUTERS
·
Feb 26

Sarepta Therapeutics to Present New Long-Term Gene Therapy and Exon-Skipping Data at 2026 MDA Clinical and Scientific Congress

Reuters
·
Feb 26

BUZZ-Sarepta falls on bigger-than-expected Q4 loss

Reuters
·
Feb 26

Stock Track | Sarepta Therapeutics Plunges 5.11% in Pre-market on Earnings Miss, CEO Retirement

Stock Track
·
Feb 26

Sarepta CEO To Jump Ship After 'Tumultuous' Year

Benzinga Earnings
·
Feb 26

U.S. RESEARCH ROUNDUP-Arcellx, Costar Group, Magnite

Reuters
·
Feb 26

Stock Track | Sarepta Therapeutics Plunges 5.32% on Q4 Earnings Miss and CEO Retirement Announcement

Stock Track
·
Feb 26

Sarepta Therapeutics Announces Planned CEO Leadership Transition

TIPRANKS
·
Feb 26

Analysts Offer Insights on Healthcare Companies: Ibio (IBIO) and Sarepta Therapeutics (SRPT)

TIPRANKS
·
Feb 26

Sarepta Therapeutics Inc - Douglas Ingram to Retire as CEO of Sarepta - SEC Filing

THOMSON REUTERS
·
Feb 26